Mark Emalfarb

560 total citations
8 papers, 357 citations indexed

About

Mark Emalfarb is a scholar working on Molecular Biology, Infectious Diseases and Biomedical Engineering. According to data from OpenAlex, Mark Emalfarb has authored 8 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Infectious Diseases and 3 papers in Biomedical Engineering. Recurrent topics in Mark Emalfarb's work include vaccines and immunoinformatics approaches (3 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Bacillus and Francisella bacterial research (3 papers). Mark Emalfarb is often cited by papers focused on vaccines and immunoinformatics approaches (3 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Bacillus and Francisella bacterial research (3 papers). Mark Emalfarb collaborates with scholars based in Finland, Netherlands and Russia. Mark Emalfarb's co-authors include Alexander V. Gusakov, А. П. Синицын, Richard P. Burlingame, О. Н. Окунев, Boris B. Ustinov, Rob Joosten, Jan C. Verdoes, Peter J. Punt, Jaap Visser and Jan Wery and has published in prestigious journals such as Frontiers in Immunology, Biotechnology and Bioengineering and Vaccine.

In The Last Decade

Mark Emalfarb

8 papers receiving 345 citations

Peers

Countries citing papers authored by Mark Emalfarb

Since Specialization

Citations

This map shows the geographic impact of Mark Emalfarb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Emalfarb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Emalfarb more than expected).

Fields of papers citing papers by Mark Emalfarb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Emalfarb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Emalfarb. The network helps show where Mark Emalfarb may publish in the future.

Co-authorship network of co-authors of Mark Emalfarb

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Emalfarb. A scholar is included among the top collaborators of Mark Emalfarb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Emalfarb. Mark Emalfarb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1 2023 ·Frontiers in Immunology ·Mariana González-Hernández, Franziska Kaiser, Imke Steffen, Małgorzata Ciurkiewicz, Geert van Amerongen, Ronen Tchelet, Mark Emalfarb, (unknown), Marilyn G. Wiebe, Marika Vitikainen, Irina C. Albulescu, Berend‐Jan Bosch, Wolfgang Baumgärtner, Bart L. Haagmans, Albert Osterhaus	1
2	A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice 2022 ·Vaccine ·Laura Lazo, Mónica Béquet‐Romero, (unknown), Alexis Musacchio, Ania Cabrales, (unknown), Luis Ariel Espinosa, Markku Saloheimo, Marika Vitikainen, (unknown), Mark Emalfarb, Ronen Tchelet, Edith Suzarte Portal, Gerardo Guillén	9
3	Toxicity and Local Tolerance of a Novel Spike Protein RBD Vaccine Against SARS-CoV-2, Produced Using the C1 Thermothelomyces Heterothallica Protein Expression Platform 2022 ·Toxicologic Pathology ·Yuval Ramot, (unknown), (unknown), (unknown), (unknown), (unknown), Marika Vitikainen, (unknown), (unknown), Ronen Tchelet, (unknown), Mark Emalfarb, Abraham Nyska	7
4	The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines 2022 ·Vaccines ·Gábor Keresztes, Mark Baer, Mark R. Alfenito, Theo C. Verwoerd, Andriy Kovalchuk, Marilyn G. Wiebe, (unknown), (unknown), Ronen Tchelet, (unknown), Gunnveig Grødeland, Mark Emalfarb	4
5	RESEARCH: Development of a mature fungal technology and production platform for industrial enzymes based on a Myceliophthora thermophila isolate, previously known as Chrysosporium lucknowense C1 2011 ·Industrial Biotechnology ·Hans Visser, Vivi Joosten, Peter J. Punt, Alexander V. Gusakov, (unknown), Rob Joosten, (unknown), Jaap Visser, А. П. Синицын, Mark Emalfarb, Jan C. Verdoes, Jan Wery	124
6	ORIGINAL RESEARCH: A dedicated vector for efficient library construction and high throughput screening in the hyphal fungus Chrysosporium lucknowense 2007 ·Industrial Biotechnology ·Jan C. Verdoes, Peter J. Punt, Richard P. Burlingame, (unknown), (unknown), (unknown), (unknown), Rob Joosten, Mark Emalfarb	31
7	Design of highly efficient cellulase mixtures for enzymatic hydrolysis of cellulose 2007 ·Biotechnology and Bioengineering ·Alexander V. Gusakov, (unknown), (unknown), Boris B. Ustinov, О. Н. Окунев, Richard P. Burlingame, Mark Emalfarb, (unknown), А. П. Синицын	169
8	Interaction between indigo and adsorbed protein as a major factor causing backstaining during cellulase treatment of cotton fabrics 1998 ·Applied Biochemistry and Biotechnology ·Alexander V. Gusakov, А. П. Синицын, (unknown), (unknown), А. В. Марков, О. Н. Окунев, (unknown), Mark Emalfarb	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact